OOIR: Observatory of International Research

Papers

(The median citation count of Blood Reviews is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Transplant-acquired allergy in HCT-recipients: Reference for clinical management	79
Pitfalls in laboratory monitoring of treatment in people with Haemophilia	78
Editorial Board	73
Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach	72
Radiation and leukaemia: Which leukaemias and what doses?	71
Artificial intelligence in sickle disease	63
Targeting CD38 in immune thrombocytopenia: Rationale and a scoping review of daratumumab	61
Beyond current treatment of Fanconi Anemia: What do advances in cell and gene-based approaches offer?	59
Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond	54
Thalassaemia in China	52
Not all LGL leukemias are created equal	50
Advances in the critical care management for patients with hematological malignancies	48
Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond	47
Targeting the neonatal Fc receptor (FcRn) in hematologic conditions with a focus on warm autoimmune hemolytic anemia	46
Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk	45
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma	45
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need	43
Ph-chromosome-negative myeloproliferative neoplasms: clonal dynamics are the name of the game	41
Chasing leukemia differentiation through induction therapy, relapse and transplantation	41
Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103]	36
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT	35
Adenovirus infection in adult allogeneic hematopoietic stem cell transplant recipients: Systematic review and meta-analysis	35
Breaking down frailty: Assessing vulnerability in acute myeloid leukemia	33
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies	33
Harnessing multi-source data for individualized care in Hodgkin Lymphoma	32

Artificial intelligence in myeloid malignancies: Clinical applications of machine learning in myelodysplastic syndromes and acute myeloid Leukemia	32
Old tests and new paradigms: How to interpret iron studies and related biomarkers for the diagnosis of iron deficiency in adults	32
Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs	32
Clostridioides difficile infection in non-transplanted adults with haematological malignancy: Systematic review and meta-analysis on behalf of European Conference on Infections in Leukemia (ECIL) and	31
Preservation of fertility in female patients with hematologic diseases	31
Gut microbiome composition and dysbiosis in immune thrombocytopenia: A review of literature	30
Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification	29
Gut dysbiosis, endotoxemia and clotting activation: A dangerous trio for portal vein thrombosis in cirrhosis	29
The acute pain crisis in sickle cell disease: What can be done to improve outcomes?	29
CHIPing away the progression potential of CHIP: A new reality in the making	28
Current challenges in conditioning regimens for MDS transplantation	27
Richter's transformation: Transforming the clinical landscape	27
Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria	27
Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies	25
Down syndrome and leukemia: An insight into the disease biology and current treatment options	25
Metabolomics in sickle cell disease: Current knowledge and gaps – A scoping review	25
Beyond the blood: A practical guide to thalassemia care in the emergency department	24
Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines	24
Editorial Board	24
The mythological chimera and new era of relapse prediction post-transplant	24
ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma	23
State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease	22
Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia	22
Addressing the surge of infections by multidrug-resistant Enterobacterales in hematopoietic cell transplantation	22
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists	21
Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?	21
Complementary and alternative medicine for children with sickle cell disease: A systematic review	21
A tale of two sites – Distinct spatial differences between bone marrow and extramedullary AML	21
Optimizing high dose melphalan	21
Αlpha-thalassemia: A practical overview	21
Access to CAR T-cell therapy: Focus on diversity, equity and inclusion	20
The role of preoperative transfusion in sickle cell disease, a systematic review and meta-analysis	20
Artificial intelligence applications in thrombotic thrombocytopenic Purpura: A systematic review of diagnostic, risk stratification, and prognostic models	20
Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape	20
Redefining central nervous system multiple myeloma: From rare phenomenon to emerging entity	19
Androgen use in bone marrow failures and myeloid neoplasms: Mechanisms of action and a systematic review of clinical data	19
Long-term durability of rAAV gene therapy in hemophilia: Factor expression, clinical outcomes and underlying molecular mechanisms	19
Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?	19
Navigating acute myeloid leukemia towards better outcomes: Treatment pathways and challenges for patients ineligible for intensive chemotherapy	19
Bridging the evidence-to-practice gap: Advancing neonatal blood transfusion. A narrative review of recent guidelines	18
Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group	17
The critical role of platelets in venous thromboembolism: Pathogenesis, clinical status, and emerging therapeutic strategies	17
Ven the dose matters: Venetoclax dosing in the frontline treatment of AML	17
Quality of life, mood disorders, and cognitive impairment in adults with β-thalassemia	17
How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?	16
Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment	16
A personalized, organ-based approach to the treatment of chronic steroid-refractory graft-versus-host disease	16
Innovations in red blood cell preservation	16
Progress, and prospects in the therapeutic armamentarium of persons with congenital hemophilia. Defining the place for liver-directed gene therapy	16
Tackling myeloma bone disease: From pathophysiology to cutting-edge therapies	16

The microbiome-lymphoma Axis: A systematic review and Meta-analysis of gut Dysbiosis pattern in diffuse large B-cell lymphoma	15
Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation	15
Vaccinations in hematological patients in the era of target therapies: Lesson learnt from SARS-CoV-2	15
The gut microbiome in B cell lymphoma	15
Erythropoiesis in lower-risk myelodysplastic syndromes and beta-thalassemia	15
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): A practical compartment-based review	15
Combining PTCy and ATG for GvHD prophylaxis in non-malignant diseases	15
The use of bone-modifying agents in multiple myeloma	15
The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators	15
De-novo immune-mediated thrombotic thrombocytopenic purpura following surgical and non-surgical procedures: A systematic review	15
The intestinal flora: The key to unraveling heterogeneity in immune thrombocytopenia?	14
Application of thrombopoietic agents in cancer therapy-induced thrombocytopenia: A comprehensive review	14
Phenotypic and functional heterogeneity of monocytes in health and cancer in the era of high dimensional technologies	14
Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme	14
Editorial Board	13
Haploidentical bone marrow transplants with post transplant cyclophosphamide on day + 3 + 5: The Genova protocol	13
Radiotherapeutics, clonal hematopoiesis, and risk of hematologic malignancies: The good, the bad, the ugly	13
Evaluation of current mouse in vivo models and advanced in vitro models for leukaemia research	13
Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS	13
Patient-reported outcomes - the missing link to advancing light chain (AL) amyloidosis clinical research	12
Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?	12
Challenges in the treatment of adolescent and young adult acute lymphoblastic leukemia: A comprehensive review	12
Dysbiosis and immunothrombosis – How platelets and the gut microbiome interact	12
Unmet needs in hemophilic arthropathy	12
Haploidentical transplants with a G-CSF/ATG-based protocol: Experience from China	12
Chronic myeloid leukaemia: Biology and therapy	12
Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution	12
Evans syndrome revisited	11
Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies	11
Disparity in hematological malignancies: From patients to health care professionals	11
Classic Hodgkin lymphoma: Pathobiological features that impact emerging therapies	11
What population-based databases reveal about equity in access to hematopoietic cell transplant and cellular therapy	11
Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML	11
Suppression to removal, an emerging therapeutic approach for AL amyloidosis: A comprehensive review with early human data and pharmacokinetics of CAEL-101 antibody	11
Neuro-toxicities of chemo- and immune-therapies in haematologic malignancies: from mechanism to management	11
Treating large B-cell lymphoma: Current strategies and unmet needs across community and academic settings	10
Editorial Board	10
Editorial Board	10
Autologous stem cell transplantation in AL amyloidosis: Muddy waters	9
Follicular lymphoma: The long and winding road leading to your cure?	9
Continuing progress in radioimmunotherapy for hematologic malignancies	9
Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives	9
Genetic landscape in coagulation factor XIII associated defects – Advances in coagulation and beyond	9
Fetal and neonatal alloimmune thrombocytopenia: Current pathophysiological insights and perspectives for future diagnostics and treatment	9
Nodal peripheral T-cell lymphoma: Chemotherapy-free management, are we there yet?	9
Editorial Board	9
The development of post-transplant cyclophosphamide: Half a century of translational team science	9
Platelet transfusion guidelines for thrombocytopenic patients in non-surgical and non-traumatic care settings: A systematic review and methodological quality assessment	9
Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH	9
Do anemia treatments improve quality of life and physical function in patients with myelodysplastic syndromes (MDS)? A systematic review	8
MRD in multiple myeloma: Moving from “minimal” to “measurable”	8
Secondary antibody deficiency in chronic lymphocytic leukemia and non-Hodgkin lymphoma: Recommendations from an international expert panel	8
CAR-T for all? Barriers, facilitators, and interventions to commercial CAR T-cell therapy access	8
Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances	8
BCL-2 inhibition in haematological malignancies: Clinical application and complications	8
Unraveling germline predisposition in hematological neoplasms: Navigating complexity in the genomic era	8
Dismantling relapsed/refractory mantle cell lymphoma	8
Editorial Board	8
Corrigendum to “Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?”[BLOOD REVIEWS, 9 August 2024, https://doi.org/10.1016/j.blre.2024.101226]	8
AI for the assessment and discovery of morphological–molecular biomarker relationships in hematologic malignancies	8
Could (should) we abandon total body irradiation for conditioning in children with leukemia	8
Towards achieving immune reset in autoimmune cytopenias: Insights from clinical experiences with B cell depleting therapies	8
Liver dysfunction in AAV-mediated Hemophilia B gene therapy: Mechanisms and management strategies	8
Biomarkers of joint and bone diseases, and their associations to haemophilic arthropathy in people with haemophilia: A first systematic review	8